coltuximab ravtansine
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2007 (NCT00549185)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19BINDING AGENT
CD19 binding agent
The mechanism of action of SAR3419 involves binding to the cell-surface antigen, followed by internalization via endocytosis and subsequent intracellular routing to lysosomes where the huB4 antibody moiety of the ADC is degraded to yield the lysine-SPDB-DM4 metabolite. Induces antibody-dependent cell-mediated cytotoxicity (ADCC) but not complement-dependent cytotoxicity (CDC). Induces cell-cycle arrest at the G2/M phase followed by an increase in apoptotic cells.
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaImmunoGen ↗
- ChEMBLCHEMBL2109286 ↗
Also known as
- coltuximab ravtansine
- coltuximab ravtansine
- sar3419
- sar3419
- sar3419
- sar 3419
- sar-3419
- sar-3419
- sar-3419
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01472887 | Phase 2 | Jan 1, 2012 | Sanofi |
| NCT01470456 | Phase 2 | Nov 1, 2011 | Sanofi |
| NCT01440179 | Phase 2 | Oct 1, 2011 | Sanofi |
| NCT00796731 | Phase 1 | Oct 1, 2008 | Sanofi, University of Lyon |
| NCT00549185 | Phase 1 | Oct 1, 2007 | Sanofi |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 5 | 5 | 2 | 2007 |
| University of Lyon | Academic/Hospital | 1 | 0 | 1 | 2008 |